AmbioPharm, Inc.

AmbioPharm, Inc. is a specialized provider of peptide manufacturing and development services, focusing on high-quality Active Pharmaceutical Ingredients (APIs) for various applications across the pharmaceutical, biotech, and cosmetic sectors. Based in South Carolina, United States and founded in 2005, AmbioPharm, Inc. , founded by Juncai (Chris) Bai, Ph.

D. , provides peptide contract development and manufacturing services (CDMO), custom peptide synthesis, peptide API development, process development, analytical support, and cGMP manufacturing services for the pharmaceutical, biotechnology, and life sciences industry. The company specializes in developing and manufacturing peptide-based active pharmaceutical ingredients (APIs) for clinical and commercial programs, serving customers worldwide through its facilities in the United States and China. In August 2026, Corden Pharma International Switzerland GmbH, a portfolio company of Astorg, acquired AmbioPharm, Inc.

from Carlyle Group and MVM Partners. AmbioPharm specializes in peptide manufacturing and development services, offering a comprehensive range of products including Active Pharmaceutical Ingredients (APIs) for peptide vaccines and various cosmetic peptide formulations. The company employs advanced synthesis techniques, including solid-phase, liquid-phase, and hybrid methods, to produce high-quality peptides catering to clients in the pharmaceutical, biotech, and cosmetic industries. Their products are utilized in a wide array of applications from preclinical research to commercial drug development, facilitating the creation of novel therapeutic solutions for rare diseases.

AmbioPharm also provides analytical development and validation services to ensure compliance with stringent quality standards, serving a diverse global market, including major pharmaceutical firms, clinical research laboratories, and cosmetic formulators. AmbioPharm operates on a B2B model, generating revenue primarily through partnerships and contracts with pharmaceutical and biotech companies, clinical research labs, and academic institutions. Transactions typically involve the provision of custom peptide synthesis services and the manufacturing of GMP and non-GMP peptides, with clients engaging AmbioPharm for both large-scale and small-batch projects. The revenue structure is based on fixed pricing agreements for custom services, offering tailored peptide products that adhere to specific requirements.

The company's flagship products include biologically active peptides for therapeutic applications and cosmetic formulations, with pricing models reflecting the complexity and scale of peptide synthesis. AmbioPharm's commitment to rapid delivery and stringent quality controls positions it competitively in the peptide manufacturing market.